News
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...
1d
MedPage Today on MSNThe Wealth and Complexity of Treatment Options for Relapsed/Refractory Multiple MyelomaFor patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...
Myeloma cells further reduced to 0.02% from immunophenotyping analysis. M-spike still remained negative, and the levels of free κ and λ chains in the serum were 5.5 and 26.9 mg/L, with a κ/λ ratio of ...
The advent of large language models has facilitated the development of natural language text generation. It also poses unprecedented challenges, with content hallucination emerging as a significant ...
During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results